MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2

Myriad Genetics, Inc. (MYGN) recently announced updates to its agreement with Illumina Inc. (ILMN) . The company’s gold-standard Genomic Instability Score (“GIS”) to determine Homologous Recombination Deficiency (“HRD”) will be reported for all samples analyzed with Illumina’s updated research assay, TruSight Oncology 500 v2 (TSO 500 v2).The latest development expands the worldwide access to Myriad Genetics’ GIS, previously available as a separate product, and better positions it as a potential companion di ...